Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study.
Funda Meric-BernstamRandy F SweisStefan KasperOmid HamidShailender BhatiaReinhard DummerAgostina StradellaGeorgina V LongAnna SpreaficoToshio ShimizuNeeltje SteeghsJason John LukeSarah M McWhirterThomas MüllerNitya NairNancy LewisXinhui ChenAndrew BeanLisa M KattenhornMarc R PelletierShahneen SandhuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The combination of MIW815 and spartalizumab, was well tolerated in patients with advanced/metastatic cancers, including in patients with anti-PD-1 refractory disease. Minimal anti-tumor responses were seen.